Overview

Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude

Status:
Completed
Trial end date:
2018-08-02
Target enrollment:
Participant gender:
Summary
This trial will evaluate the effect of acetazolamide (375 mg per day) vs. placebo on lung water content by ultrasound at acute altitude exposure in patients with Chronic Obstructive Pulmonary Disease (COPD).
Phase:
Phase 4
Details
Lead Sponsor:
University of Zurich
Collaborator:
National Center of Cardiology and Internal Medicine named after academician M.Mirrakhimov
Treatments:
Acetazolamide